Raymond James analyst Brian Peterson maintains D2L (TSX:DTOL) with a Outperform and lowers the price target from C$22 to C$16.
Dose Escalation Data From TranscendIT-101, Ascendis Pharma’s Phase 1/2 Trial Of TransCon TLR7/8 Agonist In Patients With Advanced Solid Tumors, Presented At SITC 2022
- Early signs of clinical activity were observed in patients receiving TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab; abscopal effect observed with monotherapy
- With a single
